What is HAE's health score?

HAEMONETICS CORP (HAE) has a TradeApes health score of 56 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is HAE's estimated fair value?

Based on our 5-year discounted cash flow model, HAEMONETICS CORP's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is HAE undervalued or overvalued?

Our model currently rates HAE as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for HAE... Refresh in a moment for the full analysis.

HAEMONETICS CORP (HAE)

Healthcare Inconclusive inconclusive mixed

$67.81

Updated: 2026-05-30

TradeApes Score

Financial Strength

60 Healthy

Operating Trend

68 Healthy

Relative Value

30 Weak

Capital Allocation

70 Healthy

Risk

60 Healthy

Key Findings

+ High FCF yield — above 7%, strong cash return relative to price paid

Unlock Full Report →

− Historically expensive — EV/EBITDA in top 20% of its 5-year range

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.